A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients

Trial Profile

A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Inactive Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Adalimumab (Primary) ; Prednisone
  • Indications Intermediate uveitis; Panuveitis; Posterior uveitis
  • Focus Registrational; Therapeutic Use
  • Acronyms Visual II
  • Sponsors Abbott Healthcare; AbbVie
  • Most Recent Events

    • 01 Dec 2017 Results of a post-hoc analysis from VISUAL-1 and VISUAL-2 studies assessing the association between corticosteroid dosage and incidence rates of corticosteroid-related adverse events, published in the Ophthalmology.
    • 17 Jun 2017 Results of exploratory analysis of VISUAL I and VISUAL II trials presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 13 Oct 2016 Results published in the Internet Document
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top